Proposed resolution submitted by a Shareholder on a matter included in the agenda of the EGM

With reference to current report No. 37/2025 of 24 September 2025 on the convening of the Extraordinary General Meeting of Captor Therapeutics S.A. on 22 October 2025 (“EGM”), the Management Board of Captor Therapeutics S.A. (“Company”) hereby informs that on 15 October 2025, the Company received a motion from shareholder Paweł Holstinghausen-Holsten, acting pursuant to Article 401 §4 of the Commercial Companies Code, regarding a draft resolution to item 6 of the planned agenda of the EGM concerning the establishment of an incentive programme, authorising the Company's Management Board to increase the Company's share capital within the authorised capital, authorising the Management Board to exclude the pre-emptive right to shares issued within the authorised capital in whole or in part with the consent of the Supervisory Board, and amending the Articles of Association (“Resolution”).

The submitted draft Resolution is attached to this current report.